Lineage Cell Therapeutics, Inc. (LCTX): Submission of Matters to a Vote of Security Holders
Lineage Cell Therapeutics, Inc. (LCTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0000876343 0000876343 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2
How this was made
The 30-second read
Why it matters
On June 9, 2026, after receiving comments from CIRM, LCTX withdrew its application; the company states this does not impact current and planned OPC1 development in the ongoing DOSED clinical study.
Market read
Primary tradable element is the disclosed withdrawal of a CIRM grant application; governance vote tallies are secondary.
What to watch
The filing does not quantify lost grant value or reasons for CIRM comments; traders may need the Proxy/Proxy-linked context or follow-on updates to assess whether this signals broader program risk.
Background
The company previously applied for a CIRM (California Institute for Regenerative Medicine) CLIN2 award to support continued clinical development of OPC1 for spinal cord injuries.
Ticker impact
Lineage Cell Therapeutics disclosed June 10 shareholder votes and that it withdrew its CIRM Grant application for OPC1 after CIRM comments.
Likely limited near-term impact unless investors view CIRM funding as material; focus may shift to DOSED trial progress and alternative funding.
The filing is an 8-K with final vote counts (mostly non-tradable) plus a specific, time-stamped change: withdrawal of the CIRM Grant application on June 9 following CIRM feedback, explicitly stated as not affecting ongoing/planned OPC1 development.
Market effects
Highlights funding/eligibility friction risk for regenerative medicine programs seeking state/regional grants.
Minor—CIRM is California-based; could affect sentiment around California regenerative medicine grant processes.
Low—no direct global regulatory or partnership change disclosed.
Counterpoint
Investors may discount the withdrawal if DOSED trial funding is already secured or if the grant was non-critical; the key is continued clinical execution.
Key entities
- companyLineage Cell Therapeutics, Inc.
Subject of the SEC 8-K; disclosed shareholder vote results and withdrawal of its CIRM grant application for OPC1.
- regulator/funderCalifornia Institute for Regenerative Medicine (CIRM)
State regenerative medicine funder whose comments led LCTX to withdraw its CLIN2 grant application.
- program/clinical trialOPC1 / DOSED study
OPC1 spinal cord injury program; DOSED evaluates a novel delivery device administering OPC1 to subacute and chronic SCI participants.
